Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases, such as liver fibrosis, cirrhosis and liver cancer (esp. hepatocellular carcinoma, HCC).

Alentis has in-licensed platform technologies and monoclonal antibodies which are the result of more than a decade of research from University Strasburg / INSERM.

The portfolio is based on deep competence in liver diseases and fibrosis and the discovery of a novel, very fundamental mechanism of action underlying these diseases.

Alentis has lead monoclonal antibodies which showed consistent compelling efficacy in multiple animal models of fibrosis and liver cancer.

Alentis further has a proprietary discovery platform that allows for efficient discovery of compounds and targets that are relevant in the pathology of late stage liver diseases.